CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of $365.31 million for the 12-month period ending 2020-12-26, per its 10-K filed 2021-02-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2021-02-17
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2019-12-28 was $80.51M, a 33.75% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2019-09-28 was $73.55M, a 20.77% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2019-06-29 was $44.31M, a 16.16% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2019-03-30 was $55.69M, a 4.54% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2020 was $365.31M, a 43.79% increase from fiscal 2019.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2019 was $254.06M, a 11.81% increase from fiscal 2018.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2018 was $227.22M, a 80.93% increase from fiscal 2017.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2017 was $125.59M, a 19.54% decline from fiscal 2016.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|---|
| 2020-12-26 | $365.31M 10-K · filed 2021-02-17 | |||||
| 2019-12-28 | $80.51M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | $154.06M derived: sum of 2 quarters · filed 2021-02-17 | $198.37M derived: sum of 3 quarters · filed 2021-02-17 | $254.06M 10-K · filed 2021-02-17 | ||
| 2019-09-28 | $73.55M 10-Q · filed 2019-11-06 | $117.86M derived: sum of 2 quarters · filed 2019-11-06 | $173.55M 10-Q · filed 2019-11-06 | $233.75M derived: sum of 4 quarters · filed 2021-02-17 | ||
| 2019-06-29 | $44.31M 10-Q · filed 2019-07-31 | $100.00M 10-Q · filed 2019-07-31 | $160.19M derived: sum of 3 quarters · filed 2021-02-17 | $221.10M derived: sum of 4 quarters · filed 2021-02-17 | ||
| 2019-03-30 | $55.69M 10-Q · filed 2019-05-07 | $115.89M derived: sum of 2 quarters · filed 2021-02-17 | $176.79M derived: sum of 3 quarters · filed 2021-02-17 | $229.64M derived: sum of 4 quarters · filed 2021-02-17 | ||
| 2018-12-29 | $60.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | $121.10M derived: sum of 2 quarters · filed 2021-02-17 | $173.95M derived: sum of 3 quarters · filed 2021-02-17 | $227.22M 10-K · filed 2021-02-17 | ||
| 2018-09-29 | $60.90M 10-Q · filed 2019-11-06 | $113.75M derived: sum of 2 quarters · filed 2019-11-06 | $167.02M 10-Q · filed 2019-11-06 | $137.98M derived: sum of 4 quarters · filed 2020-02-11 | ||
| 2018-06-30 | $52.85M 10-Q · filed 2019-07-31 | $106.12M 10-Q · filed 2019-07-31 | $77.07M derived: sum of 3 quarters · filed 2020-02-11 | $130.07M derived: sum of 4 quarters · filed 2020-02-11 | ||
| 2018-03-31 | $53.27M 10-Q · filed 2019-05-07 | $24.22M derived: sum of 2 quarters · filed 2020-02-11 | $77.22M derived: sum of 3 quarters · filed 2020-02-11 | $131.89M derived: sum of 4 quarters · filed 2020-02-11 | ||
| 2017-12-30 | -$29.04M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-11 | $23.95M derived: sum of 2 quarters · filed 2020-02-11 | $78.62M derived: sum of 3 quarters · filed 2020-02-11 | $125.59M 10-K · filed 2020-02-11 | ||
| 2017-09-30 | $52.99M 10-Q · filed 2018-11-07 | $107.67M derived: sum of 2 quarters · filed 2018-11-07 | $154.63M 10-Q · filed 2018-11-07 | $199.91M derived: sum of 4 quarters · filed 2019-02-13 | ||
| 2017-07-01 | $54.67M 10-Q · filed 2018-08-08 | $101.64M 10-Q · filed 2018-08-08 | $146.91M derived: sum of 3 quarters · filed 2019-02-13 | $184.60M derived: sum of 4 quarters · filed 2019-02-13 | ||
| 2017-04-01 | $46.96M 10-Q · filed 2018-05-10 | $92.24M derived: sum of 2 quarters · filed 2019-02-13 | $129.93M derived: sum of 3 quarters · filed 2019-02-13 | $165.47M derived: sum of 4 quarters · filed 2019-02-13 | ||
| 2016-12-31 | $45.27M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $82.97M derived: sum of 2 quarters · filed 2019-02-13 | $118.51M derived: sum of 3 quarters · filed 2019-02-13 | $156.09M 10-K · filed 2019-02-13 | ||
| 2016-09-24 | $37.69M 10-Q · filed 2017-11-09 | $73.24M derived: sum of 2 quarters · filed 2017-11-09 | $110.81M 10-Q · filed 2017-11-09 | $144.07M derived: sum of 4 quarters · filed 2018-02-13 | ||
| 2016-06-25 | $35.55M 10-Q · filed 2017-08-09 | $73.12M 10-Q · filed 2017-08-09 | $106.38M derived: sum of 3 quarters · filed 2018-02-13 | $144.28M derived: sum of 4 quarters · filed 2018-02-13 | ||
| 2016-03-26 | $37.58M 10-Q · filed 2017-05-10 | $70.84M derived: sum of 2 quarters · filed 2018-02-13 | $108.74M derived: sum of 3 quarters · filed 2018-02-13 | $157.99M derived: sum of 4 quarters · filed 2018-02-13 | ||
| 2015-12-26 | $33.26M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $71.16M derived: sum of 2 quarters · filed 2018-02-13 | $120.42M derived: sum of 3 quarters · filed 2018-02-13 | $152.04M 10-K · filed 2018-02-13 | ||
| 2015-09-26 | $37.90M 10-Q · filed 2016-11-02 | $87.15M derived: sum of 2 quarters · filed 2016-11-02 | $118.77M 10-Q · filed 2016-11-02 | $147.31M derived: sum of 4 quarters · filed 2016-11-02 | ||
| 2015-06-27 | $49.25M 10-Q · filed 2016-08-03 | $80.87M 10-Q · filed 2016-08-03 | $109.41M derived: sum of 3 quarters · filed 2016-08-03 | $141.71M derived: sum of 4 quarters · filed 2016-08-03 | ||
| 2015-03-28 | $31.62M 10-Q · filed 2016-05-04 | $60.16M derived: sum of 2 quarters · filed 2016-05-04 | $92.46M derived: sum of 3 quarters · filed 2016-05-04 | $128.92M derived: sum of 4 quarters · filed 2016-05-04 | ||
| 2014-12-27 | $28.54M 10-K · filed 2015-02-17 | $60.84M derived: sum of 2 quarters · filed 2015-11-04 | $97.30M derived: sum of 3 quarters · filed 2015-11-04 | $129.92M 10-K · filed 2017-02-14 | ||
| 2014-09-27 | $32.30M 10-Q · filed 2015-11-04 | $68.76M derived: sum of 2 quarters · filed 2015-11-04 | $101.39M 10-Q · filed 2015-11-04 | $120.91M derived: sum of 4 quarters · filed 2015-11-04 | ||
| 2014-06-28 | $36.46M 10-Q · filed 2015-07-30 | $69.09M 10-Q · filed 2015-07-30 | $88.61M derived: sum of 3 quarters · filed 2015-07-30 | $119.95M derived: sum of 4 quarters · filed 2015-07-30 | ||
| 2014-03-29 | $32.63M 10-Q · filed 2015-04-30 | $52.15M derived: sum of 2 quarters · filed 2015-04-30 | $83.49M derived: sum of 3 quarters · filed 2015-04-30 | $112.12M derived: sum of 4 quarters · filed 2015-04-30 | ||
| 2013-12-28 | $19.53M 10-K · filed 2015-02-17 | $50.86M derived: sum of 2 quarters · filed 2015-02-17 | $79.49M derived: sum of 3 quarters · filed 2015-02-17 | $105.42M 10-K · filed 2016-02-12 | ||
| 2013-09-28 | $31.34M 10-K · filed 2015-02-17 | $59.96M derived: sum of 2 quarters · filed 2015-02-17 | $85.89M 10-Q · filed 2014-10-30 | $108.61M derived: sum of 4 quarters · filed 2015-02-17 | ||
| 2013-06-29 | $28.63M 10-K · filed 2015-02-17 | $54.55M 10-Q · filed 2014-08-07 | $77.27M derived: sum of 3 quarters · filed 2015-02-17 | $99.66M derived: sum of 4 quarters · filed 2015-02-17 | ||
| 2013-03-30 | $25.93M 10-K · filed 2015-02-17 | $48.64M derived: sum of 2 quarters · filed 2015-02-17 | $71.03M derived: sum of 3 quarters · filed 2015-02-17 | $101.57M derived: sum of 4 quarters · filed 2015-02-17 | ||
| 2012-12-29 | $22.72M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-17 | $45.10M derived: sum of 2 quarters · filed 2015-02-17 | $75.65M derived: sum of 3 quarters · filed 2015-02-17 | $102.12M 10-K · filed 2015-02-17 | ||
| 2012-09-29 | $22.38M 10-Q · filed 2013-10-30 | $52.93M derived: sum of 2 quarters · filed 2013-10-30 | $79.40M 10-Q · filed 2013-10-30 | $106.48M derived: sum of 4 quarters · filed 2014-02-25 | ||
| 2012-06-30 | $30.55M 10-Q · filed 2013-07-31 | $57.02M 10-Q · filed 2013-07-31 | $84.09M derived: sum of 3 quarters · filed 2014-02-25 | $103.01M derived: sum of 4 quarters · filed 2014-02-25 | ||
| 2012-03-31 | $26.47M 10-Q · filed 2013-05-08 | $53.55M derived: sum of 2 quarters · filed 2014-02-25 | $72.46M derived: sum of 3 quarters · filed 2014-02-25 | $106.61M derived: sum of 4 quarters · filed 2014-02-25 | ||
| 2011-12-31 | $27.08M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $45.99M derived: sum of 2 quarters · filed 2014-02-25 | $80.14M derived: sum of 3 quarters · filed 2014-02-25 | $115.52M 10-K · filed 2014-02-25 | ||
| 2011-09-24 | $18.91M 10-Q · filed 2012-11-01 | $53.07M derived: sum of 2 quarters · filed 2012-11-01 | $88.44M 10-Q · filed 2012-11-01 | -$253.99M derived: sum of 4 quarters · filed 2013-02-27 | ||
| 2011-06-25 | $34.16M 10-Q · filed 2012-08-07 | $69.53M 10-Q · filed 2012-08-07 | -$272.90M derived: sum of 3 quarters · filed 2013-02-27 | -$297.14M derived: sum of 4 quarters · filed 2013-02-27 | ||
| 2011-03-26 | $35.38M 10-Q · filed 2012-05-04 | -$307.05M derived: sum of 2 quarters · filed 2013-02-27 | -$331.30M derived: sum of 3 quarters · filed 2013-02-27 | -$316.07M derived: sum of 4 quarters · filed 2013-02-27 | ||
| 2010-12-25 | -$342.43M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | -$366.68M derived: sum of 2 quarters · filed 2013-02-27 | -$351.44M derived: sum of 3 quarters · filed 2013-02-27 | -$334.11M 10-K · filed 2013-02-27 | ||
| 2010-09-25 | -$24.25M 10-Q · filed 2011-11-02 | -$25.23M 10-Q · filed 2010-11-04 | -$9.01M derived: sum of 2 quarters · filed 2011-11-02 | $8.32M 10-Q · filed 2011-11-02 | $5.86M 10-Q · filed 2010-11-04 | $27.46M derived: sum of 4 quarters · filed 2012-02-27 |
| 2010-06-26 | $15.23M 10-Q · filed 2011-08-03 | $32.57M 10-Q · filed 2011-08-03 | $51.71M derived: sum of 3 quarters · filed 2012-02-27 | $85.25M derived: sum of 4 quarters · filed 2012-02-27 | ||
| 2010-03-27 | $17.34M 10-Q · filed 2011-05-04 | $36.48M derived: sum of 2 quarters · filed 2012-02-27 | $70.02M derived: sum of 3 quarters · filed 2012-02-27 | |||
| 2009-12-26 | $19.14M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-27 | $52.68M derived: sum of 2 quarters · filed 2012-02-27 | $111.20M 10-K · filed 2012-02-27 | |||
| 2009-09-26 | $33.54M 10-Q · filed 2010-11-04 | $92.06M 10-Q · filed 2010-11-04 | ||||
| 2008-12-27 | -$528.48M 10-K · filed 2011-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |